Individualized Stereotactic Body Radiotherapy of Liver Metastases

Status: Recruiting
Phase: Phase 2
Diagnosis: Radiation Oncology
NCT ID: NCT01239381 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 10-139

 

Stereotactic body radiation therapy (SBRT) is a technique that is used to deliver radiation, to sites in the body. All participants in this study will be treated with SBRT using proton beam radiation. Proton beam radiation uses tiny particles to deliver radiation to tumors. The purpose of this research study is to determine if SBRT with protons will prevent tumor growth and reduce the treatment side effects for liver metastases.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Massachusetts General Hospital/ North Shore Cancer Center

Overall PI:
Harvey Mamon, MD, PhD, Brigham and Women's Hospital

Site-responsible Investigators:
Theodore Hong, MD, Massachusetts General Hospital

Contacts:
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100

Eligibility Criteria

Inclusion Criteria: - Biopsy-proven cancer diagnosis of a solid tumor with 1-4 liver metastases. There is no upper size limit. Liver metastases may be diagnosed by imaging alone, no liver biopsy is required. Extrahepatic disease is allowed if it have been stable for 3 months prior to study entry, the dominant disease burden is intrahepatic and the patient is referred for definitive radiation therapy to the disease in the liver - Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as 10mm or greater with spiral CT scan - Patients may have had prior chemotherapy, targeted biological therapy, surgery, transarterial chemoembolization (TACE), radiofrequency ablation, or cryosurgery for their disease as long as the prior therapy occured greater than 3 weeks elapsed before the first radiation treatment. Patients may not have had prior liver directed radiation, including radioembolization. - 18 years of age or older - Expected survival must be greater than three months - ECOG performance status of 0, 1 or 2 - Patients must have at least 800mL of uninvolved liver - Normal organ and marrow function as outlined in the protocol - If patient has underlying cirrhosis, only Child-Pugh classification Group A patients should be included in this study. Clinical assessment of ascites and encephalopathy is required. Child-Pugh classification must be determined for all study participants at the time of eligibility analysis. - Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation Exclusion Criteria: - Women who are pregnant or lactating - Patients with gross ascites or encephalopathy - Local conditions or systemic illnesses which would reduce the local tolerance to radiation treatment, such as serious local injuries, active collagen vascular disease, etc. - Prior liver directed radiation treatment, including selective internal radiation - No serious medical illness, which may limit survival to less than 3 months - No serious psychiatric illness which would limit compliance with treatment - Participants who have had chemotherapy or radiotherapy within 3 weeks prior to starting study treatment or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier - Participants may not be receiving any other investigational agents, or any other anti-cancer therapy during treatment - Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia. - Only solid tumors are permitted. Thus, individuals with a liver mass from a diagnosis of lymphoma or leukemia are excluded
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms